Compared to non-users, patients treated with GLP-1 RAs exhibited a statistically significant lower risk of esophageal cancer (0.04% vs. 0.13%, p < 0.0001) at the seven-year follow-up mark (14). Here, GLP1R is linked to esophageal cancer.